Catalysts / RAPP
Upcoming FDA decisions and readouts we track for Rapport Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Rapport Therapeutics (RAPP, listed on Nasdaq). They cover 2 programmes: RAP-219 (Bipolar mania (AMPA receptor modulator); Focal onset seizures — open-label safety) and RAP-219 long-acting injectable (Neurological disorders (LAI formulation)).
First on the list: the Phase 2 readout for RAP-219 (Bipolar mania (AMPA receptor modulator)), guided by the company to Oct 2026. The furthest-out event tracked is 2027. By stage, the upcoming rows are 1 Phase 1 readout, 1 Phase 2 readout and 1 Clinical readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP · Nasdaq | RAP-219 | Bipolar mania (AMPA receptor modulator) | Oct 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Rapport Therapeutics RAPP · Nasdaq | RAP-219 | Focal onset seizures — open-label safety | Q4 2026 company guidance |
Clinical readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Rapport Therapeutics RAPP · Nasdaq | RAP-219 long-acting injectable | Neurological disorders (LAI formulation) | 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList